APC

Chr 5AD

APC regulator of Wnt signaling pathway

Also known as: BTPS2, DESMD, DP2, DP2.5, DP3, GS, PPP1R46

This gene encodes a tumor suppressor protein that acts as an antagonist of the Wnt signaling pathway. It is also involved in other processes including cell migration and adhesion, transcriptional activation, and apoptosis. Defects in this gene cause familial adenomatous polyposis (FAP), an autosomal dominant pre-malignant disease that usually progresses to malignancy. Mutations in the APC gene have been found to occur in most colorectal cancers, where disease-associated mutations tend to be clustered in a small region designated the mutation cluster region (MCR) and result in a truncated protein product. [provided by RefSeq, Jun 2022]

Primary Disease Associations & Inheritance

Adenoma, periampullary, somaticMIM #175100
Adenomatous polyposis coliMIM #175100
AD
Brain tumor-polyposis syndrome 2MIM #175100
AD
Colorectal cancer, somaticMIM #114500
Desmoid disease, hereditaryMIM #135290
AD
Gardner syndromeMIM #175100
AD
Gastric adenocarcinoma and proximal polyposis of the stomachMIM #619182
AD
Gastric cancer, somaticMIM #613659
Hepatoblastoma, somaticMIM #114550
UniProtFamilial adenomatous polyposis 1
UniProtMedulloblastoma
UniProtHepatocellular carcinoma
500
ClinVar variants
69
Pathogenic / LP
1.00
pLI score· haploinsufficient
12
Active trials
Clinical SummaryAPC
🧬
Gene-Disease Validity (ClinGen)
gastric adenocarcinoma and proximal polyposis of the stomach · ADDefinitive

Definitive — sufficient evidence for diagnostic panels

2 total gene-disease associations curated

Population Constraint (gnomAD)
Highly constrained gene — heterozygous loss-of-function variants are very rare in the population (pLI 1.00). One damaged copy is likely sufficient to cause disease.
📋
ClinVar Variants
69 Pathogenic / Likely Pathogenic· 330 VUS of 500 total submissions
💊
Clinical Trials
12 active or recruiting trials — potential therapeutic options may be available

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

LoF intolerant — likely haploinsufficient
LoF Constraint?LOEUF (Loss-of-function Observed/Expected Upper bound Fraction) is the upper bound of the 90% CI for LoF OE — the preferred gnomAD v4 metric. Lower = more intolerant to LoF. LOEUF < 0.35 = highly constrained.
0.16LOEUF
pLI 1.000
Z-score 8.90
OE 0.10 (0.060.16)
Highly constrained

Highly LoF-intolerant (top ~10% of genes)

Missense Constraint?Missense Z-score: standard deviations fewer missense variants observed vs. expected. Z > 3.09 (p < 0.001) = gene does not tolerate missense variation. OE missense < 0.6 is also considered constrained.
0.17Z-score
OE missense 0.99 (0.941.03)
1436 obs / 1454.0 exp
Tolerant

Mild missense constraint

Observed / Expected Ratios?Shaded band = 90% confidence interval. Vertical tick = point estimate. Grey threshold line = gnomAD constraint cutoff for that variant class.
LoF OE?Ratio of observed to expected LoF variants. Upper CI bound (LOEUF) ≤ 0.35 = strong LoF constraint signal.0.10 (0.060.16)
00.351.4
Missense OE?Ratio of observed to expected missense variants. OE ≤ 0.6 = fewer missense variants than expected by chance.0.99 (0.941.03)
00.61.4
Synonymous OE?Control metric — synonymous variants are largely neutral and expected near OE = 1.0. Significant deviation may indicate annotation issues.1.11
01.21.6
LoF obs/exp: 11 / 113.2Missense obs/exp: 1436 / 1454.0Syn Z: -1.98

ClinVar Variant Classifications

500 submitted variants in ClinVar

Classification Summary

Pathogenic53
Likely Pathogenic16
VUS330
Likely Benign100
Conflicting1
53
Pathogenic
16
Likely Pathogenic
330
VUS
100
Likely Benign
1
Conflicting

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
45
0
8
0
53
Likely Pathogenic
12
1
3
0
16
VUS
5
270
52
3
330
Likely Benign
0
0
11
89
100
Benign
0
0
0
0
0
Conflicting
1
Total622717492500

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

Protein Context — Lollipop Plot

APC · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Gene2Phenotype Curations

APC-related adenomatous polyposis coli

definitive
ADLoss Of FunctionAbsent Gene Product
EyeSkinCancer
G2P ↗

APC-related desmoid disease, hereditary

definitive
ADUndeterminedUncertain
Skin
G2P ↗

Gene2Phenotype curations · DECIPHER consortium patient cohort (public variants) · deciphergenomics.org

OMIM — Genotype-Phenotype Relationships

1 OMIM entry

Adenoma, periampullary, somatic

MIM #175100

Molecular basis of disorder known

Adenomatous polyposis coli

MIM #175100

Molecular basis of disorder known

Autosomal dominant

Brain tumor-polyposis syndrome 2

MIM #175100

Molecular basis of disorder known

Autosomal dominant

Colorectal cancer, somatic

MIM #114500

Molecular basis of disorder known

Desmoid disease, hereditary

MIM #135290

Molecular basis of disorder known

Autosomal dominant

Gardner syndrome

MIM #175100

Molecular basis of disorder known

Autosomal dominant

Gastric adenocarcinoma and proximal polyposis of the stomach

MIM #619182

Molecular basis of disorder known

Autosomal dominant

Gastric cancer, somatic

MIM #613659

Molecular basis of disorder known

Hepatoblastoma, somatic

MIM #114550

Molecular basis of disorder known

📖
GeneReview available — APC
Authoritative clinical overview · NCBI Bookshelf · Recommended first read
Open GeneReview ↗
Clinical Literature
Landmark / reviewRecent case evidence

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

Plasma Cell Myeloma

Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment

RECRUITING
NCT05561387Phase PHASE3SWOG Cancer Research NetworkStarted 2023-10-12
BortezomibDaratumumab and Hyaluronidase-fihjDexamethasone
Acinar Cell CarcinomaAdenoid Cystic CarcinomaAdrenal Cortical Carcinoma

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

ACTIVE NOT RECRUITING
NCT02834013Phase PHASE2National Cancer Institute (NCI)Started 2017-01-30
Biospecimen CollectionComputed TomographyEchocardiography Test
Gastric CancerHealthy

Preliminary Experimental Study on Key Technologies for Early Screening of Gastric Cancer

RECRUITING
NCT05991947Zhejiang Cancer HospitalStarted 2021-03-01
No intervention
Extensive Stage Lung Small Cell Carcinoma

Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker

ACTIVE NOT RECRUITING
NCT04334941Phase PHASE2National Cancer Institute (NCI)Started 2020-07-20
AtezolizumabBiopsy ProcedureBiospecimen Collection
Acute LeukemiaAdenomatous PolyposisAdrenocortical Carcinoma

Familial Investigations of Childhood Cancer Predisposition

RECRUITING
NCT03050268St. Jude Children's Research HospitalStarted 2017-04-06
Hodgkin LymphomaNon-Hodgkin Lymphoma

Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors

RECRUITING
NCT06002828ECOG-ACRIN Cancer Research GroupStarted 2023-10-13
Biospecimen CollectionQuality-of-Life AssessmentQuestionnaire Administration
Familial Adenomatous Polyposis (FAP)Attenuated Familial Adenomatous Polyposis (AFAP)MUTYH-Associated Polyposis (MAP)

Familial Adenomatous Poliposys Italian Network (Rete Italiana Poliposi Adenomatosa Familiare)

ACTIVE NOT RECRUITING
NCT07461246Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoStarted 2024-05-13
Covid19

Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix

ACTIVE NOT RECRUITING
NCT03305341Phase EARLY_PHASE1Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB ChairStarted 2025-05-18
COVID-19 Therapeutic Biologic Mix - NOVAVAX COVID-19 VACCINE plus BCG Vaccine Mix for percutaneous use
Breast Cancer

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

RECRUITING
NCT05879926Phase PHASE3NRG OncologyStarted 2023-08-31
Ovarian Function Suppression + Aromatase InhibitorAdjuvant Chemotherapy + Ovarian Function Suppression
Prostate AdenocarcinomaStage III Prostate Cancer AJCC v8Stage IVA Prostate Cancer AJCC v8

Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

ACTIVE NOT RECRUITING
NCT04513717Phase PHASE3NRG OncologyStarted 2021-01-21
ApalutamideBicalutamideBiospecimen Collection
Breast CancerCognitive Impairments

Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors

RECRUITING
NCT05896189Phase NANRG OncologyStarted 2024-04-12
Arm 1: Computerized Cognitive Training-Global Stimulation GamesArm 2: Computerized Cognitive Training-Neuroplasticity Games
Desmoid FibromatosisRecurrent Desmoid FibromatosisUnresectable Desmoid Fibromatosis

A Study of a New Drug, Nirogacestat, for Treating Desmoid Tumors That Cannot be Removed by Surgery

ACTIVE NOT RECRUITING
NCT04195399Phase PHASE2Children's Oncology GroupStarted 2020-10-07
Biospecimen CollectionComputed TomographyEchocardiography Test